Vitara Biomedical

Name

Vitara Biomedical

Legal name

Vitara Biomedical, Inc.

Website

https://vitara.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Neonatal Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)

akta.pro secondary industry

Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG)

Keywords

• Neonatal medical devices
• Artificial womb technology
• Premature infant care
• Extrauterine support system
• Neonatal intensive care

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Sales: Vitara Biomedical plans to commercialize its EXTEND neonatal support technology as a medical device sold to hospital systems and neonatal intensive care units (NICUs). The company is currently in pre-commercial stage with first-in-human clinical studies planned. Revenue will be generated through direct sales of the EXTEND system to healthcare facilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Vitara Biomedical develops and is advancing toward commercialization of the EXTEND (EXTrauterine Environment for Neonatal Development) system, a first-of-its-kind neonatal medical device that provides a fluid-filled, womb-like environment for extremely premature newborns as early as 22 weeks gestation. The technology is designed to support infants for up to 28 days by delaying exposure to air and supporting natural organ development, with the goal of bridging the gap between birth and standard NICU care. The product is currently investigational and limited by U.S. federal law to investigational use only, with first-in-human clinical studies planned.

Product overview

Vitara Biomedical offers a single unified product: EXTEND (Neonatal Support Technology), a breakthrough first-of-its-kind neonatal artificial womb system. The technology provides a fluid-filled environment modeled on natural fetal physiology, similar to a mother's womb, for extremely premature newborns delivered as early as 22 weeks gestation. EXTEND is designed to provide up to 28 days of protective support, bridging the critical period until infants reach developmental stages where survival rates climb to nearly 90%. The company is currently advancing this investigational device toward first-in-human clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

• EXTEND: Neonatal Support Technology that provides a fluid-filled environment for extremely premature newborns for up to 28 days, designed to bridge the gap from mother to NICU.

Products and services

• EXTEND Neonatal Support Technology EXTEND (EXTrauterine Environment for Neonatal Development) is a first-of-its-kind neonatal medical device that surrounds extremely premature newborns (as early as 22 weeks gestation) in a fluid-filled, womb-like environment for up to 28 days, delaying air exposure to allow fragile lungs and vital organs to continue developing. The system uses umbilical cannulation to connect to an oxygenator, mimicking placental function, and is designed for hospital-based neonatal intensive care units treating extremely premature infants.

Quantifiable outcome

• Survival rate improvement from less than 50% to nearly 90% for extremely premature infants supported by EXTEND
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 1 January 2019Vitara Biomedical was founded based on decades of pioneering neonatology research from Children's Hospital of Philadelphia. Co-inventors Dr. Alan Flake and Dr. Marcus Davey developed the EXTEND technology through CHOP research. The company was founded in 2019 and is built on this foundational research relationship.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Dräger: Global medical and safety technology company that supplies incubators, neonatal ventilators, and NICU workflow solutions. It is comparable as the dominant incumbent supplier of NICU life-support hardware that EXTEND would sit alongside or potentially displace for the most premature infants.
• GE HealthCare: Large incumbent offering neonatal monitoring, infant warmers, and NICU imaging/ultrasound solutions. Comparable as a broad hospital-channel incumbent whose installed base and procurement relationships Vitara must engage when introducing EXTEND.
• Philips: Provides neonatal and pediatric patient monitoring, ICU solutions, and clinical decision support. Comparable as a broad incumbent in NICU monitoring and clinical workflow that hospitals procure alongside any future EXTEND platform.
• Masimo: Specializes in noninvasive patient monitoring, including neonatal pulse oximetry and physiologic monitoring technologies. Comparable as a monitoring-focused medtech that addresses similar neonatal safety and surveillance needs in the NICU.
• Medtronic: Diversified medical device company with neonatal and pediatric offerings across monitoring, ventilation, and surgical support. Comparable as a large medtech incumbent with hospital channel reach and the capital to enter adjacent neonatal life-support categories.

Direct peers

• Natus Medical (Nihon Kohden): Focused on neurology, newborn care, and hearing screening products used in NICUs and labor & delivery. Comparable as a NICU-specialized device company whose installed base and clinical relationships overlap directly with Vitara's target customer.
• Inspiration Healthcare: UK-based specialist in neonatal intensive care equipment, including incubators, warming, and respiratory support. Comparable as a neonatal-focused device company targeting the same NICU customer base with adjacent life-support hardware.

Regional players

• Atom Medical: Japan-based manufacturer specializing in neonatal and perinatal care equipment such as incubators and infant warmers. Comparable as a regional NICU device specialist competing in the same category outside of Vitara's primary U.S. market.
• Bistos: South Korean medical device company focused on neonatal care products including incubators, phototherapy, and neonatal monitors. Comparable as a regional NICU device vendor addressing similar hospital customers and clinical workflows.

Emerging players

• Partridge Lab (Toronto) / EVE Biobag research program: Academic research groups (notably at the University of Toronto / SickKids) developing competing extrauterine support / 'biobag' technologies with parallel preclinical work published in Nature. Comparable as the closest scientific parallel and potential future competitor in the artificial womb category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vitara-biomedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitara Biomedical